sumatriptan succinate / Generic mfg. - LARVOL DELTA

Multiple Sclerosis With Migraine and Pyoderma Gangrenosum Treated With Ofatumumab and Erenumab. (PubMed, Cureus) - "She experienced persistent migraines despite valproic acid and sumatriptan use. After the administration of intravenous methylprednisolone (IVMP), ofatumumab treatment was introduced; erenumab was later initiated to manage migraines...The combination therapy demonstrated effectiveness without exacerbating the patient's underlying dermatological condition. This case suggests that combining ofatumumab and erenumab is a viable therapeutic option for patients with MS and comorbid migraine and pyoderma gangrenosum, offering effective disease control with an acceptable safety profile."

Journal • CNS Disorders • Migraine • Multiple Sclerosis • Pain • Pyoderma Gangrenosum

Spatial metabolomics combined with MALDI-MSI unveils gut-brain axis mechanisms of angelica dahurica radix in migraine rats. (PubMed, Phytomedicine) - "Baizhi alleviates migraine through multi-target regulation of the gut-brain axis, including intestinal barrier repair, gut microbiota remodeling, and cerebral metabolic restoration. Notably, this study on Baizhi represents the first integration of spatial metabolomics (MALDI-MSI) with gut microbiome and systemic metabolomics to elucidate migraine mechanisms, providing a novel multi-omics strategy for understanding the holistic therapeutic effects of traditional Chinese medicine. These findings provide a mechanistic basis for its clinical application in migraine treatment."

Journal • Preclinical • CNS Disorders • Metabolic Disorders • Migraine • Pain • Solid Tumor • OCLN • TJP1 • TNFA

Treating the Pain After the Cure: Therapeutic Approaches for Post-ECT Headache-A Systematic Review. (PubMed, J ECT) - "Treatments evaluated included sumatriptan, nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, propranolol, topiramate, valproic acid, mirtazapine, dihydroergotamine, topical salicylates, cryotherapy, and percutaneous electrical nerve stimulation. However, clinical phenotyping and a stepwise therapeutic approach may improve symptom control. This review provides a comprehensive summary of current options and offers guidance for individualized management of post-ECT headache."

Journal • CNS Disorders • Migraine • Musculoskeletal Pain • Pain

Investigating organic cation transporter 1 in drug interactions: New findings from in vitro and in vivo cynomolgus monkey studies. (PubMed, Drug Metab Dispos) - "Transport assays in transfected human embryonic kidney 293 cells showed that sumatriptan, fenoterol, metformin, quinidine, and 1-methyl-4-phenylpyridinium were transported by cOCT1 at rates comparable to hOCT1 (less than 2-fold difference)...Consistent with our in vitro findings, coadministration of OCT1 inhibitors (axitinib, nintedanib, and erlotinib) significantly increased the systemic exposure of sumatriptan in monkeys. These findings offer valuable insights into the role of OCT1 in drug-drug interactions and highlight the potential of cynomolgus monkeys as a useful and potentially translational model for OCT1-mediated disposition and interactions."

Journal • Preclinical • SLC22A1

Refractory chronic cluster headache: A new therapeutic option (EHF-EHC 2025) - "Acute therapy with oral zolmitriptan 5 mg, subcutaneous sumatriptan 6 mg, and oxygen were used, with moderate effect. Preventive treatment included prednisolone and occipital nerve block during exacerbations, and verapamil, both as monotherapy and in combination with topiramate and lithium in various regimens... Treating refractory chronic cluster headache is challenging, as it is highly disabling for the patient. Although other therapies targeting CGRP have not shown clear benefit in clinical trials, especially in chronic forms, atogepant may offer a promising alternative."

Anorexia • Cardiovascular • Chronic Cluster Headache • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Hypertension • Migraine • Pain

Pharmacokinetics and safety of Lu AG09222, an antiPACAP monoclonal antibody in development for migraine prevention (EHF-EHC 2025) - " Data were included from a (1) first-inhuman single ascending dose trial in healthy participants, including a cohort with co-administered sumatriptan (Lu AG09222 n=68; placebo n=28); (2) single-dose trial in healthy Caucasian, Chinese, and Japanese participants (Lu AG09222 n=40; placebo n=12); and (3) multiple-dose trial in participants with symptomatic allergic rhinitis (Lu AG09222 n=20; placebo n=10). Lu AG09222 exhibited a consistent PK profile across dosing regimens, route of administration and race/ethnicity. Across these trials, no safety concerns were identified, and Lu AG09222 was generally well-tolerated."

Clinical • PK/PD data • Allergic Rhinitis • CNS Disorders • Immunology • Inflammation • Migraine • Pain • ADCYAP1

Comparative analysis of efficacy between sumatriptan and naratriptan in the abortive treatment of migraine (EHF-EHC 2025) - "Sumatriptan and Naratriptan are both effective in the abortive treatment of oral migraine; however, they possess distinct characteristics. Therefore, factors such as time to pain relief, duration of effect, recurrence rate of attacks, and cardiovascular adverse effects should be considered. Thus, the choice between the two medications should be made based on the patient's profile and clinical needs for attack control, considering both efficacy and safety profile."

Clinical • Cardiovascular • CNS Disorders • Migraine • Pain

Clinical-genotype machine prescription for migraine – A HUNT study (EHF-EHC 2025) - " In total, 475 participants tried a preventive (amitriptyline, beta-blocker, candesartan or topiramate) and 565 a triptan (371 sumatriptan) during the project period. We developed models that predicted treatment responses to amitriptyline, beta-blockers, candesartan and topiramate with modest accuracy. Incorporating genetic data did not enhance performance, although the limited sample size prevents firm conclusions. Figure 1."

Clinical • CNS Disorders • Migraine • Pain

Behavioural characterisation of a codeine-induced medication overuse headache model in mice: Focus on pain-related behaviour and cognitive impairment (EHF-EHC 2025) - "After the 12-day drug-free period (day 21), we assessed the development of periorbital allodynia following application of a low nitroglycerin dose. Codeine induced cutaneous allodynia and cognitive impairment in mice, with effects comparable to those of sumatriptan. These results support the idea of codeine-induced model of MOH as a promising preclinical tool for studying MOH and its consequences. Fig."

Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Migraine • Pain

Recurrent severe headache with a background of functional vomiting and normal brain MRI, in paediatric reversible cerebral vasoconstriction syndrome (RCVS) (EHF-EHC 2025) - "Sumatriptan had made his headaches worse... After the diagnosis of RCVS, he was started on oral Nimodipine and his headaches events reduce in frequency and severity to once a day... RCVS is a rare condition normally seen in middle age. The pathogenesis is unknown and recurrence is uncommon. Severe cases can lead to stroke due to vasoconstriction."

Cardiovascular • Chronic Kidney Disease • CNS Disorders • Cognitive Disorders • Migraine • Pain • Pediatrics

Paracetamol (Acetaminophen) and caffeine combination in headache management (EHF-EHC 2025) - "Two other TTH clinical trials have shown that the efficacy and safety of combination was comparable to Naproxen 550 mg and Ibuprofen 400 mg. One randomized, cross-over trial has shown a comparable efficacy/safety profile of the combination vs sumatriptan 50 mg in treatment of migraine attack. Caffeine accelerates and prolongs the analgesic effect of paracetamol over time with a significant improvement of pain relief in patients with primary headaches without added safety issues."

CNS Disorders • Migraine • Pain • ADORA2A

Arc-mediated synaptic plasticity regulates cognitive function in a migraine mouse model (EHF-EHC 2025) - " C57BL/6 mice were randomly divided into four groups: the IS group (migraine model induced by inflammatory soup, IS), IS+M group (IS model + memantine treatment), IS+S group (IS model + sumatriptan treatment), and a control group (PBS with no IS stimulation). Cognitive dysfunction in the migraine model was associated with impaired synaptic plasticity, as indicated by reduced Arc expression. Memantine treatment alleviated cognitive deficits and restored synaptic function, suggesting that Arcmediated synaptic plasticity may play a critical role in migraine-related cognitive impairment and could be a potential therapeutic target. Fig."

Preclinical • ADHD (Impulsive Aggression) • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Migraine • Pain

Does heterogeneity in patient population, study design, and endpoint definitions affect indirect comparisons of acute migraine treatments? A methodological assessment (EHF-EHC 2025) - "[6] who reported changes in the relative effect of sumatriptan over time. ITCs of acute migraine trials, sometimes conducted decades apart, acknowledge heterogeneity but did not attempt to statistically adjust for it. More sophisticated analytical approaches are needed to obtain unbiased and reliable estimates of indirect comparative effectiveness."

Clinical • Heterogeneity • CNS Disorders • Migraine • Pain

Dynamic boronate ester crosslinked hyaluronic acid hydrogel patch enabling fast dissolution and rapid oral mucosal delivery of amorphous sumatriptan. (PubMed, Carbohydr Polym) - "Cytocompatibility and in vivo oral ulcer healing evaluations demonstrated favorable biocompatibility and therapeutic efficacy. This work presents a promising platform for rapid, effective, and patient-friendly oral mucosal drug delivery."

Journal

Cardiac arrest following sumatriptan intake: a case report of a complex diagnostic process. (PubMed, Pol Arch Intern Med) - No abstract available

Journal • Cardiovascular

The divergent roles of tryptophans W354 and W217 in OCT1 transport: similar localization, distinct functions. (PubMed, J Biol Chem) - "Hepatic organic cation transporter 1 (OCT1, SLC22A1) has a broad spectrum of structurally diverse substrates, including drugs like morphine, metformin, sumatriptan, and fenoterol. Our data suggest that W354 is crucial for OCT1 function by mediating the switch from an inward- occluded to inward-open conformation but is not directly involved in substrate interaction. In contrast, W217, along with the previously known F244, contributes to the substrate specificity of OCT1."

Journal • SLC22A1

2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies. (PubMed, Headache) - "Prochlorperazine IV and GONB must be offered to eligible adults presenting to the ED with a migraine attack for treatment of headache requiring parenteral therapy (level A - must offer) in those without contraindications, while hydromorphone IV must not be offered (level A - must not offer). Treatments that should be offered when appropriate (level B - should offer) include dexketoprofen IV, ketorolac IV, metoclopramide IV, sumatriptan SC, and SONB. Chlorpromazine IV, dexamethasone IV, and valproate IV may be offered (level C - may offer). Paracetamol IV may not be offered (level C - should not offer). Eptinezumab should be offered (level B) only for patients matching the clinical trial population but is rated level U - no recommendation for an ED-specific population. Additional evidence is needed for caffeine, granisetron, ibuprofen, ketamine, lidocaine, normal saline, propofol, and SPG blocks, all currently rated level U - no recommendation."

Journal • CNS Disorders • Migraine • Pain

A review on gut microbiota and migraine severity: a complex relationship. (PubMed, Inflammopharmacology) - "It is worth noting that research highlights several innovative treatments for migraine, such as Zelirex and Cevimide, implantable devices like Cefaly and Revilion, and new effective routes of administration for Sumatriptan. Finally, patients' perspectives and concerns were thoroughly discussed, with a focus on future directions in the migraine-gut axis research."

Journal • Review • CNS Disorders • Gastrointestinal Disorder • Migraine • Pain

Effects of Olcegepant, Sumatriptan, and Ibuprofen on Migraine-Like Behavior Induced by Repetitive Restraint Stress in Mice (Neuroscience 2025) - "These injections were repeated for sumatriptan on Day 3, while olcegepant was injected on Day 2, and Day 3. We showed that restraint stress can cause migraine-like behaviors that are responsive to several migraine therapeutics. These data further validate this model as being translationally relevant for testing migraine therapeutics and they provide insight into the mechanisms by which stress causes behavioral features consistent with migraine."

Preclinical • CNS Disorders • Migraine • Pain

Characterization of the isosorbide dinitrate model of headache in male and female rats (Neuroscience 2025) - "Pretreatment with the mu opioid receptor agonist morphine sulfate (0.3, 1, 3, and 6 mg/kg, SC), 5-HT1B/1D agonist sumatriptan (0.1, 0.3 and 1 mg/kg, IP), CGRP receptor antagonist olcegepant (0.3, 1, and 3 mg/kg, IP), and delta opioid receptor agonist SNC80 (3, 10, and 30 mg/kg, SC) suppressed the development of ISDN-induced facial allodynia in a dose-dependent manner. Additionally, we are planning to evaluate non-evoked behavioral pain endpoints (i.e. orbital tightening) and altered sensitivity associated with migraine (i.e. photophobia/phonophobia) to further characterize this model. The data to date support the use of this model to identify potential treatments for headache disorders as part of the NIH HEAL initiative to identify novel, non-opioid treatments for pain."

Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Migraine • Pain

In vivo PK, side effect profile, and analgesic efficacy of clinically used compounds in male and female rats demonstrating the established approach of the NIH HEAL Initiative Preclinical Screening Platform for Pain (PSPP) to profile potential novel analgesics. (Neuroscience 2025) - "In efficacy studies, sumatriptan provided minimal improvements on acute mechanical allodynia in the plantar incision and SNL models but did not show efficacy in guarding behavior in the plantar incision model or cold allodynia in the SNL model. The results of these studies of clinically used compounds within the PSPP program demonstrate the validation of the models and endpoints described and highlight the goal of providing a robust platform to accelerate the discovery and preclinical development of non-opioid, non-addictive treatments for pain"

Adverse events • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain

Population Pharmacokinetics of Atogepant for the Prevention of Migraine. (PubMed, Clin Pharmacokinet) - P3 | "The pharmacokinetics of atogepant are similar in healthy participants and patients with CM or EM. Dose adjustments owing to intrinsic factors of age, sex, race, and body weight, or owing to concomitant medications consisting of P-glycoprotein (P-gp) inhibitors, BCRP inhibitors, oral contraceptive components (ethinyl estradiol and levonorgestrel), famotidine, esomeprazole, sumatriptan, acetaminophen, and naproxen are not necessary. Atogepant's popPK model provides a valuable tool for evaluating specific questions for patients, healthcare providers, and regulatory agencies. Integration into other modeling approaches has also aided in model-informed drug development decisions."

Journal • PK/PD data • Breast Cancer • CNS Disorders • Hepatology • Migraine • Oncology • Pain • Renal Disease • Solid Tumor

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System. (Business Standard) - "The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Imitrex STATdose System, 4 mg/0.5 mL and 6 mg/0.5 mL, of GlaxoSmithKline Intellectual Property Ltd. England. Sumatriptan injection is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache."

ANDA • Migraine • Pain

Characteristics and management of headache among psychiatric outpatients at a Japanese general hospital: A retrospective study with an exploratory CGRP case series. (PubMed, PCN Rep) - "At the agent level, acetaminophen (n = 38), loxoprofen (n = 33), zolmitriptan (n = 14), goreisan (n = 8), sumatriptan (n = 6), kakkonto (n = 6), diclofenac (n = 4), valproic acid (n = 4), and naratriptan (n = 3) were among the most frequently listed. CGRP-targeted therapy yielded headache relief even under psychiatric comorbidity, while psychiatric symptoms did not uniformly improve, underscoring the need for parallel mental-health interventions alongside headache-specific care. Strengthening cross-specialty pathways and early headache evaluation within psychiatry are warranted."

Journal • Retrospective data • Autism Spectrum Disorder • Bipolar Disorder • Cardiovascular • CNS Disorders • Depression • Genetic Disorders • Mental Retardation • Migraine • Pain • Post-traumatic Stress Disorder • Psychiatry • Rheumatology • Schizophrenia • Social Anxiety Disorder

Susac syndrome and associated diagnostic challenges: a case report. (PubMed, J Med Case Rep) - "This case underscores the diagnostic complexity of Susac syndrome and the importance of considering it in young patients with unexplained persistent headaches progressing to encephalopathy. Early magnetic resonance imaging and timely intervention with immunosuppressive therapy are critical for managing the disease and preventing irreversible sequelae."

Journal • CNS Disorders • Immunology • Migraine • Otorhinolaryngology • Pain • Rare Diseases • Vasculitis